Frequently Searched

Week in Review: FDA Costing Lives, New Hope for Patients, and A Costly Bailout

December 2, 2018

December 2, 2018

FDA Overcaution Is Costing Lives—but Lifesaving Reform Is Possible

The delays caused by the U.S. Food and Drug Administration’s risk-averse approach to drug approvals can be harmful—and even deadly—to patients.

But in his new report, Goldwater Institute National Investigative Reporter Mark Flatten explains that times may be changing when it comes to approving potentially lifesaving treatments. Read more in this Goldwater Institute report.

VIDEO: New Hope for Patients Like Jordan


When Jordan McLinn was three years old, he was diagnosed with a fatal form of muscular dystrophy called Duchenne. His family left the children’s hospital in their hometown of Indianapolis with no options, but then they heard about a new experimental drug that could help Jordan.

Watch this video to learn more about Jordan’s story.

Romney Was Right, the GM Bailout Goes Bust, and Taxpayers Pay the Price


“Let Detroit go bankrupt,” former presidential candidate Mitt Romney wrote in 2008, arguing that the federal government should not bail out the failing domestic auto industry for their poor management decisions.

This week’s announcement from General Motors that it will close two plants in Metro Detroit and lay off 14,700 workers helps prove Romney right, albeit ten years later. Read more on the In Defense of Liberty blog.



More on this issue

Donate Now

Help all Americans live freer, happier lives. Join the Goldwater Institute as we defend and strengthen freedom in all 50 states.

Donate Now

Since 1988, the Goldwater Institute has been in the liberty business — defending and promoting freedom, and achieving more than 400 victories in all 50 states. Donate today to help support our mission.

We Protect Your Rights

Our attorneys defend individual rights and protect those who cannot protect themselves.

Need Help? Submit a case.

Get Connected to Goldwater

Sign up for the latest news, event updates, and more.